reports
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarte...
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results ZUG, Switzerland and BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the fourth quarter and full year ended December 31, 2025. “As we close out the fourth quarter, CRISPR Therapeutics continues to make steady progress across a broad and increasingly mature pipeline,” said Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics. “We made meaningful advances across multiple clinical and pr...
Monthly information on share capital and company voting rights
Monthly information on share capital and company voting rights (Article 223-16 of General Regulation of the French financial markets authority) PARIS, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting rights01/31/2026100,590,994105,825,481 For further information on Cellectis, please contact: Media contacts: Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93 Investor Relations contact: Arthur S...
Information mensuelle relative au nombre total des droits de vote et d...
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) PARIS, 04 févr. 2026 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth ISIN code: FR0010425595 DateNombre total d’actions composant le capital socialNombre total de droits de vote31/01/2026100 590 994105 825 481 Pour de plus amples informations sur Cellectis, veuillez contacter : Contacts média : Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, Patricia Sosa Navarro, Chief of...
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing ...
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) LONDON and GAITHERSBURG, Md., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the Compensation Committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 113,650 American Depositary Shares, representing an equal number of ordinary shares, to 22 employees pursuant to the C...
CRISPR Therapeutics AG: 1 director
A director at CRISPR Therapeutics AG sold 90,000 shares at 57.403USD and the significance rating of the trade was 76/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
- Jacob Mekhael
Autolus Aucatzyl launch success, FY25 preliminary revenue in line with...
Yesterday before US market opens, Autolus announced preliminary unaudited 4Q25 and FY25 net product sales of Aucatzyl (obe-cel, CD19 CAR-T), and provided a business update. $ 75m in FY25 Aucatzyl sales is in line with CSS ($ 75.9m) and ahead of our estimate of $ 72.5m. We believe this figure makes Aucatzyl's first year on the market a success, and we view FY26 guidance of $ 120-135m as within reach. Pipeline wise, we look forward to initial data from the phase 1 trial of Aucatzyl in the difficul...
- Jacob Mekhael
- Livio Luyten
- Mathijs Geerts Danau
- Wim Hoste
CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 20...
CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones -2026 is poised to be a data- and milestone-rich year across the portfolio- -CASGEVY® launch acceleration continues, supporting multi-billion-dollar potential- -Broad pipeline supported by leading gene-editing and siRNA platforms across cardiovascular, autoimmune, oncology and rare diseases- -Starting 2026 with a strong balance sheet with approximately $2 billion in cash, cash equivalents, and marketable securities- ZUG, Switzerland and BOSTON, Jan. 12, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Na...
Autolus Therapeutics Announces Preliminary Unaudited Fourth Quarter an...
Autolus Therapeutics Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Net Product Revenue, Pipeline Advancements and Outlook for 2026 Company expects preliminary unaudited AUCATZYL® net product revenue of approximately $24 million for the fourth quarter of 2025 and approximately $75 million for the full year of 2025Autolus anticipates full year 2026 AUCATZYL® net product revenue of $120 million to $135 millionIndependent real-world AUCATZYL® data from ROCCA consortium confirm high level of clinical activity with favorable safety profile Focus for 2026 is: Driving AUCATZYL®...
Cellectis Announces 2026 Strategy and Catalysts
Cellectis Announces 2026 Strategy and Catalysts NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today outlined its strategic priorities and key catalysts expected for 2026. “2025 was a transformational year for Cellectis, as we transitioned to a late-stage development allogeneic CAR-T company with the initiation of a pivotal Phase 2 trial for lasme-cel.” said André Choulika, Ph.D., Chief Executive ...
Cellectis annonce sa stratégie et ses jalons attendus en 2026
Cellectis annonce sa stratégie et ses jalons attendus en 2026 NEW YORK, 08 janv. 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS) (la « Société »), société de biotechnologie de stade clinique, qui utilise sa plateforme pionnière d'édition de génome pour développer des thérapies innovantes pour le traitement de maladies graves, présente aujourd'hui ses priorités stratégiques et les principaux jalons attendus en 2026. « 2025 a marqué un tournant stratégique pour Cellectis : nous avons franchi une étape majeure en devenant une société de biotechnologie au stade cli...
- Jacob Mekhael
Autolus To assess feasibility of Cellares' platform for CAR-T manufact...
Yesterday before US market opens, Autolus announced that it will assess the feasibility of Cellares' Cell Shuttle platform to complement its commercial manufacturing operations at the Nucleus facility in the UK. This evaluation could open the door for Autolus to expand its manufacturing to meet future demand from the larger autoimmune indications, which would likely require more than the 2000 batches per year capacity that the existing Nucleus facility is able to produce. $ 9 TP and BUY maintain...
- Jacob Mekhael
- Livio Luyten
Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® ...
Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell Shuttle™ Platform Autolus will evaluate Cellares’ fully automated, high-throughput manufacturing platform in preparation for expansion into new indications SOUTH SAN FRANCISCO, Calif. and LONDON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, and Cellares Corp, the first Integrated Development and Manufacturing Organization (IDMO),...
Monthly information on share capital and company voting rights
Monthly information on share capital and company voting rights (Article 223-16 of General Regulation of the French financial markets authority) PARIS, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting rights12/31/2025100,339,441105,576,356 For further information on Cellectis, please contact: Media contacts: Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93 Investor Rel...
Information mensuelle relative au nombre total des droits de vote et d...
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) PARIS, 05 janv. 2026 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth ISIN code: FR0010425595 DateNombre total d’actions composant le capital socialNombre total de droits de vote31/12/2025100 339 441105 576 356 Pour de plus amples informations sur Cellectis, veuillez contacter : Contacts média : Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, Patricia Sosa N...
CRISPR Therapeutics to Present at the 44th Annual J.P. Morgan Healthca...
CRISPR Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference ZUG, Switzerland and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 8:15 a.m. PT in San Francisco. A live webcast of the presentation will be available on the "Events & Presentations" page in the Investors section of ...
CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Z...
CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies -Four autoimmune patients treated to date demonstrate deep B-cell depletion sustained for at least 28 days; initial efficacy data suggest significant clinical improvement in patients dosed at the 100 million cell dose, with the first systemic lupus erythematosus (SLE) patient achieving Definitions of Remission in SLE (DORIS) remission through Month 6- -An additional Phase 1 basket trial has been initiated for zugo-cel in refractory primary imm...
Cellectis Announces Arbitral Decision in Dispute with Servier
Cellectis Announces Arbitral Decision in Dispute with Servier NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announces that the Arbitral Tribunal has issued its decision in the arbitration proceedings against Les Laboratoires Servier and Institut de Recherches Internationales Servier IRIS SARL (“Servier”), relating to the License, Development and Commercialization Agreement entered into between Ser...
Cellectis annonce la décision du tribunal arbitral dans le litige l’op...
Cellectis annonce la décision du tribunal arbitral dans le litige l’opposant à Servier NEW YORK, 15 déc. 2025 (GLOBE NEWSWIRE) -- Cellectis (la « Société ») (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique, qui utilise sa plateforme pionnière d'édition de génome pour développer des thérapies cellulaires et géniques innovantes pour le traitement de maladies graves, annonce que le tribunal arbitral a rendu sa décision dans l’arbitrage l’opposant aux sociétés Les Laboratoires Servier et Institut de Recherches Internationales Servier IRIS SARL (“Servier”), ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.